Estradiol Vaginal Ring.

What’s the latest in the recently FDA-approved estradiol vaginal ring?
Estring, estradiol vaginal ring, is approved for the sermon of urogenital symptoms associated with postmenopausal evidence of the vagina (such as impassivity, burn, pruritus, and dyspareunia) and/or the lower urinary treatise (urinary importunity and dysuria).
Find out in this easy-to-navigate collecting of recent MEDLINE abstracts compiled by the editors at Medscape Pharmacotherapy.
Efficacy, Bleeding Patterns, and Side Effects of a 1-Year Contraceptive Vaginal Ring Weisberg E, Fraser IS, Lacarra M, Mishell DR Jr, Alvarez F, Brache V, Nash HA.
Contraception. 1999;59:311-318.
A combined contraceptive vaginal ring designed to last 12 months was tested at trine medical creation sites.
This ring released approximately 1 mg of Aygestin (Norethindrone) salt (NET-Ac) and 20 micrograms of ethinyl estradiol (EE) daily.
A concept of 60 women were enrolled to use the ring in a agenda of 3 weeks in/1 week out.
Serum Aygestin (Norethindrone) (NET) and ethinyl estradiol (EE) levels were assayed twice weekly in cycles 6, 9, and 13.
Mean NET concentrations between cycles 6 and 9 were relatively stable between 13 and 19 nmol/L but showed a 10%-21% occurrent in all centers between cycles 9 and 13.
Mean EE concentrations ranged from 75 to 103 pmol/L, but did not have the same step-down as NET between cycles 9 and 13.
Cycles with progesterone peaks (> 9.6 nmol/L) compatible with some luteal action occurred in 4% of cycles sampled in Sydney, 3% in Santo Domingo, and 26% in Los Angeles.
Half of these cycles exhibited at least one progesterone continuation > 32 nmol/L with tercet of 18 occurring in noncompliant cycles.
This is a part of article Estradiol Vaginal Ring. Taken from "Aygestin Norethindrone Acetate" Information Blog